About, ownership & disclosures
Released: · Last reviewed:
Compounded GLP-1 Guide is an evidence-led consumer health publication, provider-comparison platform, pricing database, pharmacy-verification resource, and research library covering compounded semaglutide, compounded tirzepatide, telehealth programs, required fees, pharmacy transparency, regulatory developments, clinical evidence, and patient safety. It is published by US Peptides Partners LLC and is not a government agency, regulator, medical board, pharmacy board, healthcare provider, or pharmacy.
Our mission
This publication exists because the compounded-GLP-1 market is unusually hard for a consumer to navigate honestly. Prices are quoted in incompatible ways, mandatory fees hide beneath low headlines, the difference between an approved product and a compounded one is routinely blurred, and pharmacy quality — the thing that most determines what you actually receive — is often undisclosed. Our purpose is to make that market legible: to normalize prices so they can be compared, to separate what's verified from what's merely claimed, to explain the regulatory and safety context in plain language, and to give consumers the tools to verify providers and pharmacies themselves. We measure success by whether a reader leaves better able to make an informed decision, not by whether they click through to any particular provider.
How we make money
Compounded GLP-1 Guide is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report. That sentence appears once, in the footer of every page, and it is the whole of our commercial disclosure policy: the cost tables are sorted by arithmetic, every price carries the date we read it on the provider's own page, and every outbound link is marked rel="nofollow noopener".
Ownership & material-relationship disclosure
The site is published by US Peptides Partners LLC. The publisher has a commercial (affiliate/referral) relationship with NexLife, our #1 overall program under the v4.1 rubric described in the methodology. NexLife's position in the cost tables is set by its price on the read date like every other program, and the tables show programs that charge less than NexLife where they exist. For other covered programs the publisher reports no material relationship as of October 15, 2026; that is a publisher statement, not an independent audit.
Editorial standards
- Primary sources first: FDA, NIH/PubMed, ClinicalTrials.gov, CMS, state boards, court records, official labels, then provider first-party pages — never other comparison sites as primary sources for pricing or regulatory facts.
- No provider is guaranteed a place in a cost table: the tables are re-sorted from each read.
- No fake urgency, countdowns, stock levels, preselected providers, compensation-based ordering, or forced email walls.
- Medical and regulatory claims follow the language rules in methodology v4.1; every page names its medical reviewers in the author block.
How we verify information
Every commercial figure on the site traces to a record in our public evidence ledger, with a source, capture date, verification status, and confidence level. We distinguish provider-reported claims from independently verified facts, we suppress figures that conflict rather than averaging them, and we label every price with the date and page we read it on. Pricing follows a documented normalization methodology, and the underlying datasets are downloadable so anyone can check our arithmetic. Where we haven't yet verified something, we say so — "unverified" appears throughout the site precisely because we won't dress a claim up as a fact.
What we are not
We are a consumer health publication and comparison resource, and it's as important to say what that excludes. We are not a government agency, regulator, medical board, or pharmacy board — we have no authority over any provider or pharmacy. We are not a healthcare provider or pharmacy — we prescribe nothing, dispense nothing, and sell no medication. We are not a substitute for professional medical advice — nothing on the site diagnoses, treats, or tells you what to take. And we are not "official," "government approved," or affiliated with any regulator. Decisions about whether a compounded product is appropriate, at what dose, from which provider, belong to you and a licensed clinician who knows your history.
Corrections
To report an error, email corrections@compoundedglp1guide.com with the page URL and the issue. Material corrections are noted visibly on the affected page with the date of the change; publication dates are never backdated or refreshed cosmetically. A substantiated correction enters the evidence ledger like any other piece of evidence, with the reporter's claim distinguished from what we independently verify.
How our rankings stay honest
Two orders exist here and they never mix. The overall order follows the published v4.1 rubric (seven weighted categories, 100 points), with NexLife #1 at 94/100; other programs are listed alphabetically until their v4.1 re-score is complete. The cost tables follow all-in monthly cost on the read date, low to high, whoever that favours. A "lowest" statement on this site is always scoped to the programs we track on a stated date, never to the whole market.
Team
Research is led by Dr. Parmis, medical researcher (Western University of Health Sciences). Pages are medically reviewed by Dr. Jonathan Snipes, MD (NPI 1821250077) and Kim Callender, NP (FNP-BC) (NPI 1144661760); both NPI records are public in the CMS NPPES registry. Every page shows its release date, its last-reviewed date and the reviewers in the author block.